Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0002453 (amenorrhea)
 6,245 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The combination of hypercortisolism and usually low androgen and estrogen levels is frequently observed in female long distance athletes. In order to find a useful model system for studying the underlying mechanisms, the following studies were performed. The effect of cortisol on the secretion of testosterone (T) and estradiol-17 beta (E2) by human granulosa-luteal cells was studied in vitro in cultures of cells recovered from mature follicles of gonadotrophin stimulated women (participating in the IVF program). Following 24 hours of culture in tissue culture medium without hormonal additives, the granulosa-luteal cells were incubated for 6 hours in media with addition of 4-androstene-3,17-dione (A-4) as precursor and hMG and cortisol in different combinations. The secretion of T was significantly stimulated by cortisol but not by human menopausal gonadotrophin (hMG). Cortisol, but not hMG, also increased the secretion of E2, although this effect was not statistically significant. These in vitro findings make a direct effect of cortisol upon ovarian sex steroid secretion less likely as the mechanism behind the subnormal sex steroid levels in female long distance athletes. Instead, inadequate gonadotrophic stimulation, related to hypothalamic amenorrhea, and/or a selective decrease in the adrenal secretion of precursor steroids, may be an explanation.
 ...
PMID:Effect of cortisol on the secretion of testosterone and estradiol-17 beta by human granulosa-luteal cell cultures. A model system for analyzing hormonal alterations in female athletes. 133 68

Frozen cryoprotected donor sperm can be used for IVF.ET. Short administration of Gn.RH analogue with HMG and HCG (Decapeptyl) are used in 39 cycles. Seven clinical pregnancies were obtained, including one which resulted from the transfer of frozen embryos. One spontaneous abortion occurred after 7 weeks amenorrhea. Pregnancy rates are 17.9% per induction cycle, 24.1% per oocyte recovery and 26.9% per embryo transfer. Cumulative pregnancy rate for one year (3 attempts at donor sperm IVF.ET) is 44.7%, but 69.9% if we consider patients who have previously benefited from 12 to 24 AID cycles. The AID success rate is 66% for the 12 months of the first year, 42.3% in the second year and 24.2% in the third year of treatment. These data make it possible to use donor sperm with IVF.ET if tubal disease is associated with severe male factors and if the women fail to conceive after 12, 18 or 24 AID cycles, depending on their age and the existence of hormonal, cervical, tubal or pelvic associated factors.
 ...
PMID:[Fertilization in vitro with frozen donor sperm after ovocyte stimulation with an LH-RH analog, HMG, and HCG using a short-term protocol]. 314 4

The authors report the results of four IVF attempts, performed on the same couple, in 16 months, because of tubal problems. June 1985 (T1): spontaneous miscarriage after 8 weeks of amenorrhea; october 1985 (T2): negative tap; january 1986 (T3): extra-uterine pregnancy; october 1986 (T4): rejected because of "poor response" and spontaneous extra-uterine pregnancy during the same cycle.
 ...
PMID:[Risks of fertilization in vitro]. 336 76

In vitro fertilization and embryo transfer was carried out in a couple that has been infertile for 7 years. High titers of antisperm autoantibodies in the husband's serum are (table, see text) believed to be the main cause of their infertility. Prolonged methylprednisolone treatment of the man combined with artificial insemination remained unsuccessful. In two IVF attempts embryos were obtained and replaced using capacitated sperm of the husband. A pregnancy was established in the second IVF cycle, but a spontaneous abortion followed after 6 weeks of amenorrhea.
 ...
PMID:Successful in vitro fertilization with sperm cells from a man with immune infertility. 392 39

The case reported consists of thrombosis of the left internal jugular vein occurring on the 22nd week of amenorrhea of a pregnancy achieved by IVF. No etiological factor other than biochemical ovarian hyperstimulation was found. Maternal outcome was positive but intrauterine fetal death occurred 7 weeks later at 29 weeks of amenorrhea. The late occurrence of this thrombosis after ovarian hyperstimulation need to be stressed.
 ...
PMID:[Internal jugular vein thrombosis during pregnancy after ovarian hyperstimulation for in vitro fertilization]. 795 91

An 28-year-old Moroccan woman with primary infertility and OLIGO-amenorrhea was referred for hysteroscopic synechiolysis. When a diagnostic hysteroscopy was performed, a bizarre, irregular, 'cloudy' endometrium was seen. The diagnosis endometrial tuberculosis was confirmed by histological examination. Treatment with antituberculosis drug therapy resulted in a normal menstrual cycle. A normal endometrium and uterine cavity was seen at control hysteroscopy. Because of extensive irreparable tubal damage this patient will be offered IVF treatment.
 ...
PMID:[Tuberculosis as an unusual cause of oligoamenorrhea and infertility]. 903 39

Within 6 years (1991-97), a total of 680 diagnostic hysteroscopies were performed at the Day Clinic of the 1st Department of Obstetrics and Gynecology of the University of Athens ("Alexandra" Hospital). The procedure was done without general or other forms of anesthesia, using the Siegler method of approach. However in 12 cases with cervical stenosis (1.7%) and 21 patients with marked nervousness (3.1%) general anesthesia proved inevitable. The leading indication was repeated failure of IVF (54.7%), while other indications included abnormal bleeding, amenorrhea and oligomenorrhea, a history of abortions, and infertility. Abnormal hysteroscopic findings were observed in 276 cases (40.5%) among which intrauterine adhesions, endometrial hyperplasia and polyps were the most common. We had no major complications or fatalities in our series and hysteroscopy proved to be a very useful, accurate and safe method of assessing uterine and endometrial functional status.
 ...
PMID:Day clinic diagnostic hysteroscopy in a state hospital. 1045 46

Premature Ovarian Failure is a heterogeneous disorder with numerous causes. The exact prevalence of POF is unknown. In this study, we want to make Differentiate diagnosis of hypergonadotropic amenorrhea and to determine the difference between them. Retrospective, we follow up 475 women at which we perform ovarian stimulation and we observe that 6 (1.3%) have Gonadotropin resistant ovary syndrome in IVF-centre--MU--Varna.
 ...
PMID:[Diagnostic and clinical status of premature ovarian failure]. 1457 66

Aromatase inhibitors (AI) block the last enzymatic step of estrogen production, the aromatization of the A-cycle of aromatizable androgens and particularly, androstenedione (D4) and testosterone (T). Molecules designed for interfering with aromatase activity have existed for many years. Yet the activity of products of the aminogluthetimide era was too unspecific and these substances carried too many side effects for being used clinically. Today, however, 3rd generation AIs have become available that are highly specific and essentially devoid of side effects. These molecules have recently been approved for treating breast cancer in post-menopausal women, either in advanced forms, or as part of adjuvant therapy. In women whose ovaries are active, a temporary inhibition of E2 production will activate gonadotropins and in turn, stimulate follicular growth. In cancer patients, this property precludes the use of AIs in women whose ovaries are still active, unless gonadotropins are blocked. In infertile patients, this property of AIs has been put to play for inducing ovulation. AIs have been used both in women who do not ovulate but whose hypothalamo-pituitary-gonadal (HPG) axis is active (oligo-anovulators of PCOD type) and in those who ovulate regularly but in whom multiple ovulation is sought for treating infertility or as part of IVF. Like CC, AIs are not usable in women whose gonadotropins are suppressed, as in the case of hypothalamic amenorrhea. The sum of data available on the use of AI for inducing ovulation remains however meager to this date and is mainly constituted of pilot and non-randomized trials. Yet mounting evidence tends to support AIs' advantages over CC for induction of ovulation. Hence, we think that these drugs will play a key role for the induction of ovulation in the future.
 ...
PMID:[Use of aromatase inhibitors in infertile women]. 1614 May 57

Aromatase inhibitors (AI) block the last enzymatic step of estrogen production, the aromatization of the A-cycle of aromatizable androgens and particularly, androstenedione (delta4) and testosterone (T). Molecules designed for interfering with aromatase activity have existed for many years. Yet the activity of products of the aminogluthetimide era was unspecific and these substances carried too many side effects for being used clinically. Newer third generation AIs, however, are highly specific and essentially devoid of side effects. These molecules have recently been approved for treating breast cancer in postmenopausal women either, in advanced forms or, as part of adjuvant therapy. In women whose ovaries are active, a temporary inhibition of E2 production will raise gonadotropins and in turn, stimulate follicular growth. In cancer patients, this property precludes the use of AIs in women whose ovaries are still active, unless gonadotropins are blocked. But in infertility patients, this property of AIs has been put to play for inducing ovulation. AIs have been used both in women who do not ovulate but whose hypothalamo-pituitary-gonadal (HPG) axis is active (oligo-anovulators of PCOD type) and those who ovulate regularly but in whom multiple ovulation is sought for treating unexplained infertility or as part of IVF. Like clomiphene citrate (CC), AIs are not usable in women whose gonadotropins are suppressed, as in the case of hypothalamic amenorrhea. The sum of data available on the use of AI for inducing ovulation remains however meager to this date and is mainly constituted of pilot and non-randomized trials. Yet mounting evidence tends to support AIs' advantages over CC for induction of ovulation. Hence, we think that the likelihood that these drugs will play a key role in induction of ovulation in the future is high. AIs appear particularly interesting for treating unexplained infertility because AI-FSH/hMG regimens are lighter than FSH-only regimens while retaining the high pregnancy rates of these latter treatments.
 ...
PMID:Clinical use of aromatase inhibitors (AI) in premenopausal women. 1868 52


1 2 Next >>